What is Synfini?
Synfini Inc., based in Menlo Park, California, is a trailblazer in agile chemistry, leveraging an advanced, automated molecular discovery platform. The company is revolutionizing drug discovery through a sophisticated integration of neuro-symbolic AI, discovery-focused robotic automation, and high-caliber chemistry data. Synfini's innovative solutions empower researchers in academia, biotechnology, and major pharmaceutical firms globally to accelerate molecular discovery.
How much funding has Synfini raised?
Synfini has raised a total of $8.9M across 1 funding round:
Other Financing Round
$8.9M
Other Financing Round (2025): $8.9M with participation from JSL Health Capital, Foothill Ventures, Mana Ventures, and Gaingels
Key Investors in Synfini
JSL Health Capital
JSL Health Capital is a venture capital firm operating within the health sector, likely focusing on investments in companies at various stages of development within the healthcare and life sciences industries.
Foothill Ventures
Foothill Ventures is an investment firm that backs startups across software, life science, and deep tech, with a preference for pre-seed, seed, and Series A funding rounds.
Mana Ventures
Mana Ventures is a venture capital firm specializing in advanced technologies such as AI, software, health tech, biotech, and robotics, aiming to support founders in scaling their businesses.
What's next for Synfini?
The substantial enterprise-level funding and recent strategic investment signal a pivotal growth phase for Synfini. This capital infusion is expected to fuel further development of its AI-driven discovery platform and expand its automation capabilities. The company is well-positioned to deepen its impact on drug discovery pipelines for academic institutions and major pharmaceutical partners, potentially leading to accelerated therapeutic development and market penetration.
See full Synfini company page
